Wednesday, July 15 2020 10:31

ArmInfo. The experimental vaccine against COVID-19, which is being developed by the American company Moderna, was able to elicit an immune response in all  volunteers at an early stage of the study. Relevant data published in  the journal New England Journal of Medicine, reports INTERFAX.RU

The study showed, the source notes, that some antibodies were  produced after a single dose of the vaccine, but four weeks later a  second dose was required, after which the vaccine elicited a strong  immune response in all 45 volunteers. According to Moderna CEO Stefan  Bansel, the results are "encouraging and represent an important step  forward in the clinical development of mRNA-1273, our candidate for  the COVID-19 vaccine".

According to the results published on Tuesday, the most frequently  reported adverse events after administration of the second  vaccination at a dose of 100 mcg were fatigue, chills, headache and  muscle soreness, which quickly passed and manifested themselves in  mild or moderate degrees. The study involved 45 healthy volunteers  aged 18 to 55 at Seattle and Emory University in Georgia.  Participants in the experiment were given three dose levels of Modern  vaccine at 25, 100 and 250 micrograms.  On July 27, Moderna is  expected to begin a much larger study of the third-stage vaccine  trial, which will bring together 30,000 participants in 87 locations.

According to Moderna, one group will be given 100 micrograms of the  vaccine on the first day, and then again on the 29th day. The second  group will receive for comparison two doses of placebo.  Note that  the co-founder and president of the Moderna biotechnology company is  an American businessman of Armenian origin

Nubar Afeyan. Back in April of this year, the businessman noted that  by the end of spring there will be results that can prove a safe  vaccine approach. <Currently, 50 people are participating in the  trials. Then we will move on to the second stage, in which more  people will participate, and through various experiments we will  begin to understand how much is most effective in the case of this  vaccine. We hope this takes a few more months. We hope that by the  beginning of autumn we will be able to move on to the third and final  stage. We already have enough evidence that gives reason to hope that  we will succeed>, said Nubar Afeyan then.